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1. Introduction
Carbonic anhydrases (CAs) are zinc-containing metalloenzymes present in prokaryotes and
eukaryotes (Sly and Hu 1995). CAs have been investigated since 1930´s (Meldrum and
Roughton 1933). They are important in normal human physiology, e.g., in gluconeogenesis,
lipogenesis, ureagenesis, bone resorption, and formation of gastric juice and cerebrospinal
fluid (Sly and Hu 1995, Pastoreková et al. 2004). There are at least 15 members in human alpha-
CA family: Five active family members are cytosolic (CA I-III, VII, and XIII), four are membrane
associated (CA IV, IX, XII, and XIV), two are mitochondrial (CA VA and VB), and one is a
secretory form (CA VI). In addition, there are three acatalytic forms, which are called CA-
related protein (CARPs). CAs can be categorized to catalytically active or inactive, intracellular
or extracellular, and wide-spread or restricted to few tissues.
Their main physiological fuction is to catalyze the conversion of CO2 to bicarbonate ion and
proton, as described by the following reaction:
CA
CO2+ H2O↔HCO3-+ H+
In addition to their functions in normal physiology, the roles of CAs in different diseases have
been extensively investigated during the last decades. They are involved in certain neurolog‐
ical and hereditary disorders, oedema, and most importantly, in cancer. There are at least three
tumor associated isoforms; CA II, IX and XII. Especially carbonic anhydrase IX (CA IX) has
been associated to neoplastic growth and cancer. The following chapter will discuss the role
of CA IX in brain tumors.
© 2013 Nordfors et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Carbonic anhydrase IX
Carbonic anhydrase IX was first found by Pastroreková et al. (1992) and the CA9 gene was
cloned by the Pastrorek et al. (1994). Previously, a research group from Netherlands described
a monoclonal antibody, named G250, which stained cell membranes of renal cell carcinoma,
but did not stain normal epithelium (Oosterwijk et al. 1986). They continued their studies to
establish G250 as a tool in cancer diagnostics and treatment. Afterwards, the protein recog‐
nized by the G250 antibody was characterized to be CA IX (Grabmaier et al. 2000).
CA 9 gene was originally located to the chromosome 17q21.2 by fluorescence in situ hybridi‐
zation (Opavský et al. 1996), but it was later localized to the chromosome 9p13-p12 by radiation
hybrid mapping (http://www.ncbi.nlm.nih.gov/gene/768). CA9 gene consists of eleven exons
and ten introns (Opavský et al. 1996), and encodes a protein containing 466 amino acids. It has
a proteoglycan (PG) domain, central catalytic (CA) domain, transmembrane anchor, and short
COOH- terminal cytoplasmic tail. CA IX was initially called MN, found from human carcino‐
ma cell line, and later associated to neoplastic growth in carcinomas of ovary, uterine cervix
and endometrium (Závada et al. 1993). A detailed characterisation of human CA IX protein
has has shown that the recombinant CA IX protein exhibits the highest catalytic activity ever
measured for any CA isozyme (Hilvo et al. 2008).
3. Carbonic anhydrase IX in normal tissue
The expression of  CA IX in normal  tissues has  been thoroughly investigated.  In  mouse
tissues, the highest expression has been detected in gastric mucosa, moderate expression in
colon and brain, whereas low expression has been reported in pancreas and small intes‐
tine (Hilvo et al. 2004). The similar distribution pattern has been detected in human tissues;
high  CA  IX  staining  has  been  discovered  in  GI-tract,  especially  in  the  epithelia  of  the
gallbladder and gastric mucosa (Pastorek et al. 1994, Pastoreková et al. 1997, Saarnio et al.
1998a). Furthermore, Saarnio et al. (1998b) have reported the most intensive signals of CA
IX  in  the  epitelium  of  the  duodenum  and  jejunum,  whereas  the  expression  diminishes
towards the large intestine. Mesothelium, epithelial cells of the esophagus, and pancreatic
and biliary ducts express CA IX (Turner et al. 1997, Pastoreková et al. 1997, Kivelä et al.
2000, Ivanov et al. 2001). CA IX has been detected in the male reproductive organs, whereas
the female reproductive tract express only low amounts of CA IX (Liao et al. 1994; Karhumaa
et al. 2001). Generally, expression of CA IX is generally low in the human brain, although
positive signal has been reported in the epithelial cells of the choroid plexus (Ivanov et al.
2001, Proescholdt et al. 2005). Similarly, lower levels of CA IX mRNA have been reported
in the normal brain as compared to brain neoplasms (Said et al. 2007a).
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4. Carbonic anhydrase IX in neoplastic tissue
The von Hippel–Lindau (VHL) tumor suppressor gene was the first link to the major pathway
controlling CA IX expression (Wykoff et al. 2000). Importantly, CA IX turned out to be one of
the enzymes regulated by the hypoxia pathway, in which hypoxia inducible factor 1 (HIF-1)
plays a role as a key transcription factor, especially in hypoxic tumors. Under normoxia, the
encoded VHL protein (pVHL) binds to hydroxylated hypoxia inducible factor 1 – alpha and
causes degradation by the ubiquitin-mediated proteasome system, inactivating the down‐
stream target genes. (Ivanov et al.1998). HIF-1 is stabilized under hypoxic conditions and binds
to hypoxia-responsive elements in many genes, e.g VEGF, erythropoietin, and glucose
transporter. This leads to the induction of erythropoiesis, angiogenesis, and glycolysis
(Carmeliet et al. 1998). HIF-1 also activates CA9 gene and CA IX expression level increases
dramatically in hypoxic conditions. In line with this, high CA IX expression is often found in
perinecrotic regions of tumors (Wykoff et al. 2000). The similar induction of CA IX has been
proposed to take place in brain tumors. CA IX mRNA has been studied in human malignant
glioma cell lines and distinct patterns of hypoxic expression of CA IX have been observed (Said
et al. 2007b). The finding indicated that low oxygen concentration is probably the driving force
for the increased CA IX expression due to the presence of a hypoxia responsive element (HRE)
in the CA9 promoter (Wykoff et al. 2000). The activation of hypoxia-inducible genes is
illustrated in Figure 1.
Figure 1. Activation of hypoxia-inducible genes. Under normoxia, HIFα is degraded by ubiquitin-proteasome system.
Prolyl-4-hydroxylases (PHD) hydroxylate two conserved proline residues of HIF-1α, then von Hippel-Lindau protein
(VHL) binds to the hydroxylated HIF-1α. Under hypoxia, PHDs are inactive in the absence of dioxygen, and HIF-1α is not
recognized by VHL protein. HIF-1α accumulates and is translocated to the nucleus. HIF-1β constitutive subunit dimeriz‐
es with HIF-1α, resulting in the active transcription factor, which binds to hypoxia response element (HRE). Therefore
the transcription of target genes, such as CA9 and GLUT1, is induced. Adapted from Pastoreková et al. (2008) and
Haapasalo (2011).
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The overexpression of CAIX in majority of renal cell carcinomas (RCCs) is due to the loss of
functional VHL protein, which causes the stabilization of HIF-1. (Gnarra et al. 1994, Wykoff et
al. 2000). In other words, the CAs are no longer regulated by hypoxia. On the contrary, the
majority of tumors do not contain VHL mutations, and in these, CA IX is usually found in focal
perinecrotic areas, supporting the role of hypoxia in CA IX regulation (Wykoff et al. 2000).
Furthermore, it has been suggested that HIF activates genes that change the expression profile
of tumor cells suffering from hypoxia; thus, either leading to adaptation to the hypoxic stress
or resulting in cell death. If this adaptation is successful, the surviving tumor cell population
is associated with increasingly aggressive behaviour involving invasion and metastases,
resistance to anti-cancer treatment, and finally, worse patient prognosis. (Harris 2002). This
mechanism is supported by various immunohistochemical studies in which the CA IX
expression is located in in the perinecrotic regions of solid tumors.
The mechanisms behind the role of CA IX in cancer have been studied widely. The hypoxia,
measured by needle electrores, has been shown to correlate with CA IX expression in cervical
cancer (Loncaster et al. 2001). This finding has been further clarified in genetic analysis,
showing that CA9 was the most induced gene among the 32 identified hypoxia responsive
genes, which included VEGF, in human solid tumors (Lal et al. 2002). In vitro, CA9 has been
shown to be hypoxia-regulated in glioblastoma cells (Said et al. 2008).
The pivotal feature of the malignant tumor cells is their capability to maintain the normal
intracellular pH, whereas the extracellular pH is significantly acidic. CA IX increases the
extracellular acidification by shifting the site of CO2 hydration from intra- to extracellular
(Svastová et al. 2004). This in turn increases the capability of tumor cells to survive and invade,
and the selective sulfonamide inhibitors disturb this process. Acetazolamide, a potent CA
inhibitor, has been shown to suppress the invasion of renal cancer cells in vitro (Parkkila et al.
2000b). Interestingly, CA IX has an optimal catalytic activity for CO2 hydration to bicarbonate
and proton in acidic pH (Innocenti et al. 2009). Furthermore, when studied in cancer-derived
cell lines, CA IX diminishes the intracellular pH gradient in the hypoxic core of three-dimen‐
sional tumor spheroids (Swietach et al. 2008). These findings support the theory that CA IX is
an essential factor for tumor cells in adaptation to hypoxia and their survival, and is illustared
in Figure 2.
Even though the expression of CA IX is mainly regulated by hypoxia, it has been shown that
acidosis increases CA IX expression via a hypoxia-independent mechanism (Ihnatko et al.
2006). CA IX has been proposed to be regulated by low oxygen concentrations or constitutive,
oncogene-related mechanisms (Said et al. 2007a). Furthermore, CA IX modulates E-cadherin
mediated cell adhesion by decreasing the binding of this cell adhesion molecule to beta-catenin
(Svastová et al. 2003). This, in turn, could possibly benefit the cancer cells by an increase in cell
motility and invasion. As mentioned before, acetazolamide can suppress the invasion of renal
cancer cells in vitro (Parkkila et al. 2000b). However, the inhibition of CA IX in RNAi-treated
breast cancer cells reduced the invasion capacity only slightly (Robertson et al. 2004). There is
also evidence that CA IX expression is a negative predictive factor when evaluating the
treatment efficacy in oestrogen receptor-positive tumors treated with adjuvant tamoxifen after
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primary chemo-endocrine therapy (Generali et al. 2006). The role of CA IX in resistance to
chemotherapy could be explained by the effects of pH on tamoxifen uptake.
Ectopic expression of CA IX is induced in various tumors. These include the malignancies of
breast, cervix uteri, esophagus, kidney, and lung (Liao et al. 1994, McKiernan et al. 1997, Liao
et al. 1997, Turner et al. 1997, Vermylen et al. 1999, Bartosová et al. 2002). When these tumors
are considered, CA IX is absent in the corresponding normal tissue. Conversely, CA IX
expression is usually absent or reduced in tumors which have originated from CA IX-positive
tissues. These include carcinomas of stomach and gallbladder (Saarnio et al. 2001, Leppilampi
et al. 2003). This makes the CA IX a promising molecule as a prognostic factor as well as a
potential target for therapeutic methods.
In cervical cancer, the CA IX expression correlates to tumor hypoxia and poor patient prog‐
nosis, and could be used in the selection of suitable patients for hypoxia-modification therapies
(Loncaster et al. 2001). In lung cancer CA IX is a marker of poor prognosis (Swinson et al.
2003, Kim et al. 2004), and it has been associated to proteins linked to angiogenesis, disruption
of cell-cell adhesion and inhibition of apoptosis (Giatromanolaki et al. 2001). CA IX could also
been used as a differentiation tool between preneoplastic lesions and lung cancer (Vermylen
et al. 1998) and a high concentration of CA IX in plasma serves as a independent prognostic
Figure 2. Example of pH regulation in a cancer cell under hypoxia. This is controlled by HIF-1 mediated gene activa‐
tion. The rapid metabolic rate requires glucose which is transported to the cell by the glucose transporter (GLUT1).
Glycolysis produces lactate and protons, which are transported to extracellular space by the H+/monocarboxylate
transporter 4 (MCT4). The transmebrane CA IX (and XII), and cytosolic CA II prevent intracellular acidification and
maintain the physiological pH. Anion exchangers (AE) transport bicarbonate to cytosol, which then buffers the pro‐
tons produced by the active metabolism. Resulting CO2 is secreted from the cell by diffusion. The Na+/H+ exchanger 1
(NHE1) participates in the secretion of proton. The HIF-mediated machinery and oncogenic pathways result in secre‐
tion of protons and CO2 to extracellular space, thus promoting the breakdown of the extracellular matrix and invasion
of tumor cells. Adapted from Pastoreková et al. (2008) and Haapasalo (2011).
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biomarker in patients with non-small cell lung cancer (Ilie et al. 2010). CA IX expression is
sensitive for diagnostics of mesothelioma and metastatic clear cell renal cell carcinoma of the
lung (Ramsey et al. 2012). Furthermore, CA IX expression has been associated with poor
prognosis for patients with head and neck cancer (Beasley et al. 2001, Koukourakis et al.
2001), esophageal cancer (Birner et al. 2011), ovarian cancer (Hynninen et al. 2006, Choschzick
et al. 2011), soft tissue sarcoma (Måseide et al. 2004), and bladder carcinoma (Hoskin et al.
2003). It has been confirmed in several studies that CA IX correlates with poor prognosis in
breast cancer (Chia et al. 2001, Brennan et al. 2006, Hussain et al. 2007) and is related to
overexpression of c-erbB2 (Bartosová et al. 2002).
The most widely investigated tumor type, considering CA IX, is renal cell carcinoma (RCC) in
which CA IX represents a useful marker (Liao et al. 1997, McKiernan et al. 1997, Parkkila et al.
2000a). In its most common subtype, clear cell carcinoma, CA IX expression is higher than in
other renal cell cancer types (Sandlund et al. 2007). In addition, patients with both conventional
renal cell cancer and low CA IX expression had a less favourable prognosis. In renal cancer
CA IX is a promising therapeutic target for novel oncological applications, including immu‐
notherapy and radioisotopic methods (Pastoreková et al. 2006, Bleumer et al. 2006). CA IX and
CA XII are functionally involved in tumor growth (Chiche et al. 2009). Renal cell cancer in
vivo experiments showed that CA9 gene silencing alone led to a 40% reduction in xenograft
tumor volume, and silencing of both CA9 and CA12 resulted in an 85% reduction in tumor
volume.
5. Carbonic anhydrases in adult brain tumors
The incidence of brain tumors is similar in different countries and rather stable over the past
two decades (Pollack et al. 2011). There are about 50 new pediatric and 1000 adult brain tumors
every year in Finland with five million habitants (Statistics Finland 2011). The etiology of brain
tumors has been under intense investigation but no clear evidence between different environ‐
mental, nutritional or lifestyle and carcinogenesis have been found (Baldwin et al. 2004). Most
common primary CNS tumors of the adult are gliomas and meningiomas. Glioblastoma is a
highly malignant and unfortunately common, glial tumor and the 5-year survival of the
patients is less than 10 % (Stupp et al. 2009). On the other hand, almost all (90-98%) patients
with meningioma are alive after five years (Statistics Finland 2011).
The expression of carbonic anhydrases in brain tumors has been previously reported (Parkkila
AK et al. 1995). The first findings assessed CA II, which was stained positively by immuno‐
histochemistry in astrocytic tumors, oligodendrogliomas and medulloblastomas. The expres‐
sion of CA IX was first reported by Ivanov et. al (2001). In this first study, they screened tumors
of different genetic background as well as several malignant cell lines for the expression of CA
IX. mRNA analysis revealed high-to-moderate levels of expression of CA9 and CA12 in glioma
cell lines. Immunolocalization of CA IX was further studied in 11 gliomas; low-grade gliomas
were not stained for CA IX, whereas grade III-IV gliomas were all CA IX positive. In addition,
3 oligodendrogliomas were included in the analysis and they failed to express CA IX. Fur‐
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thermore, all hemangioblastomas (3 tumors), meningiomas (5 tumors), and two out of three
choroid plexus tumors were positive for CA IX.
This overview of different tumors was followed by a study of Proescholdt et al. (2005) on CA
IX and CA XII, which combined brain tumors of different histology and grade of malignancy.
The material consisted of total of 112 tumor samples (grade I-IV astrocytomas, meningiomas,
metastases, primitive neuroectodermal tumors (PNETs), and hemangioblastomas). Generally,
low-grade astrocytomas did not show any positive staining for CA IX and the expression
increased with increasing WHO grade. The strongest staining of all glioma samples was
observed in the glioblastomas, and almost all of the samples (97%) were positive. In these, the
staining was detected around necrotic areas. However, more diffuse staining pattern without
any association to necrosis was detected and CA IX expression was found in almost all tumor
cells, including those near blood vessels, suggesting the induction also without the hypoxia-
inducible mechanism. In the meningiomas, increased CA IX staining, with diffuse and evenly
distributed pattern, was found in comparison to the normal brain. The authors found the most
widespread CA IX and XII staining of all tumors in hemangioblastoma samples.
As to brain tumors, the first large study to describe the expression of CA IX in human diffusely
infiltrating astrocytomas was published year after (Haapasalo et al. 2006). The study material
consisted of 362 diffusely infiltrating astrocytoma samples (grades II-IV), which were obtained
from surgically operated patients. Cellular CA IX immunopositivity was observed in 78% of
diffusely infiltrating astrocytomas and the percentages according the WHO grade were as
follows; 65% of grade II astrocytomas, 73% of grade 3 astrocytomas, and 82% of grade 4
astrocytomas. The immunohistochemial results were verified by mRNA analysis. The
statistical comparison of cytoplasmic CA IX intensity and tumor grade revealed significantly
higher CA IX intensity in tumors of higher malignancy grade. Again, CA IX was expressed in
areas close to the necrotic regions and cytoplasmic staining was seen in the neoplastic cells of
the infiltrative zone. When important clinicopathologial features were assessed, CA IX showed
no association with p53 expression nor did it correlate with epidermal growth factor receptor–
amplification, apoptosis, or cell proliferation by Ki-67/MIB-1. There was a significant correla‐
tion between increasing CA IX intensity and increasing patient age. For the first time, CA IX
positivity was associated to shortened patient survival in univariate analysis: CA IX intensity
divided the tumors into four significantly differing prognostic subsets (Figure 3). The survival
difference was even significant within grade II and grade IV tumors separately. Most impor‐
tantly, statistical analysis of the data revealed that the patient age, tumor grade, and CA IX
intensity all had independent prognostic value when evaluated by Cox multivariate analysis.
The finding that CA IX predicts poor prognosis has been confirmed by others. Korkolopoulou
et al. (2007) showed that increasing CA IX immunopositivity was associated with a shortened
survival in univariate analysis. Furthermore, they reported similar independent prognostica‐
tors in multivariate analysis including CA IX, tumor grade and patient age. The perinecrotic
distribution of CA IX immunostaining was detected and intensity increased in parallel with
the extent of necrosis and histological grade. In concordance, Sathornsumetee et al. (2008)
conducted a trial, in which patients with recurrent malignant astrocytomas treated with a
combination of VEGF -neutralizing antibodies were retrospectively evaluated. Survival
Carbonic Anhydrase IX in Adult and Pediatric Brain Tumors
http://dx.doi.org/10.5772/52358
539
analysis revealed that high CA IX expression was associated with poor survival outcome.
VEGF was associated with radiographic response but not with survival. Interestingly, they
tested both CA IX and HIF simultaneously in a Cox model as separate factors, and only CA IX
remained as a statistically significant factor. One opposite result has been published in glioma
patient cohort (Flynn et al. 2008). In this study, no significant correlations between the CA IX
expression and patient survival or tumor grade were found, although the patients with CA
IX-positive tumors seemed to have a trend towards a worse prognosis. This might be due to
different immunostaining method used. The most reliable method for CA IX immunostaining
having no cross-reactivity with other CAs (Saarnio et al. 1998b), is based on M75 antibodies
used by us and e.g. Korkolopoulou et al. (2007). Flynn et al. (2008) had also smaller number of
patients. Yoo et. al (2010) assessed the issue again, and showed that CA IX expression was a
predictive factor for poor survival and correlated positively with increasing WHO grade.
The expression of CA IX has been studied in other gliomas as well. Järvelä et al. (2008) showed
by immunohistochemistry that 80% of studied 86 oligodendroglial tumors stained positively
for CA IX. In addition, CA IX predicted poor prognosis in univariate analysis and in multi‐
variate analysis CA IX expression, patient age and histological component (pure oligoden‐
droglioma vs. mixed oligoastrocytoma) showed independent prognostic values. Abraham et
Figure 3. Prognostic significance of CA IX in diffusely infiltrating astrocytomas (grades II-IV). Kaplan-Meier curves are
shown (p = 0.0011, log-rank test). Haapasalo J et al. (2006)
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al. (2012) have recently assessed the expression of all hypoxia related molecules HIF-1, VEGF,
Glut-1, and CA IX, in oligodendrogliomas. They found that all these proteins were statistically
significantly different between grade II and III oligodendrogliomas, anaplastic oligodendro‐
gliomas having stronger expression. Ingterestingly, low CA IX expression predicted better
prognosis in anaplastic oligodendrogliomas but not in grade II oligodendrogliomas, whereas
the prognostic significance was not reported in the whole tumor material.
As for mostly benign tumors, Yoo et al. (2007) showed that 50% of all meningiomas contained
regions of hypoxia as judged by expression of CA IX. CA IX expression was significantly
associated with higher-grade histology and tended to be more common in recurrent tumors.
Futhermore, Korhonen et al. (2009) reported 11.6% cytosolic CA IX expression in meningiomas.
CA IX positivity was neither associated with the studied clinicopathological factors nor
survival.
Recently, Jensen et al. (2012) assessed the molecular markers of hypoxia, vascularity, and
proliferation in meningeomas, including CA IX. As expected, VEGF, HIF, CA IX, and Glut-1
were positively correlated. There was an association between higher-grade tumors with higher
scores for CA IX, VEGF, and HIF-1alpha, but CA IX was not associated to overall survival.
CA IX is also significantly upregulated in craniopharyngiomas and is associated with increased
cyst size (Proescholdt et al. 2011). The mechanisms of CA IX regulation remain unknown, since
neither hypoxia nor p53 appear to play a role in these tumors. The authors state, that inhibition
of CA IX may be a potential target for the adjuvant treatment in patients with cystic cranio‐
pharyngiomas.
6. CA IX in pediatric brain tumors
Pediatric cancers are still the main cause of death in children aged 1-14 years in the UK and
Finland (Gatta et al. 2005, Statistics Finland 2011). After leukemia brain tumors are the second
most common tumor group. Approximately 60-70% of the patients with brain tumors are alive
five years from the diagnosis (Pokhrel and Hakulinen 2009). The most common pediatric brain
tumors are pilocytic astrosytoma, medulloblastoma and ependymoma. Neurosurgical
operation is the most important treatment modality. Inoperable or highly malignant tumors
are treated also with radio- and chemotherapy. CNS is vulnerable, especially when evolving.
Most of the patients do survive but the tumor and the different treatment modalities can cause
side effects that reduce the quality of life. Supratentorial tumors, tumor reoperations, shunt
revisions and chemotherapy increase the risk of these problems (Reimers et al. 2003, Pietilä et
al. 2012). There is only a limited scope for improvement with conventional chemotherapy and
thus, there is an urgent need of therapeutic agents for these patients. CA IX is one novel
molecule that might serve as a prognostic/diagnostic tool, and perhaps, a target for various
therapeutic methods.
Some publications have assessed the CA IX expression in pediatric brain tumors. Ivanov et al.
(2001) screened a small amount of brain tumors and found the following inmmunohistochem‐
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istry results: most of the 7 central/peripheral PNETs expressed the CA IX, all of 6 studied
epedymomas were posivive. Preusser et al. (2005) assessed the CA IX in intracranial ependy‐
momas: 84 out of 100 tumors expressed CA IX, and it was associated with a bizarre angiogen‐
esis and necrosis. However, CA IX failed to reach a prognostic significance in univariate
analysis. The most common, solid, extracranial pediatric nervous tumor is neuroblastoma.
Dungwa et al. (2012) found positive membranous/cytoplasmic CA IX expression in 21 (23%)
of 91 neuroblastomas but was absent in ganglioneuromas. Neuroblastomas with 1p deletion
and MYCN amplification had even stronger membranous expression. 18% of the neuroblas‐
tomas showed nuclear CA IX expression in 10% or more tumoral cells. Nuclear CA IX
expression associated with worse overall –and event-free survival.
We have previously studied CA IX in 39 medulloblastomas and PNETs (Nordfors et al. 2010).
CA IX positivity was found in 23% of tumors and the expression was linked to necrosis. CA
IX expression was analysed in concordance with various clinical features and molecular
markers. Proliferation (Ki-67/MIB-1), apoptosis or expression of Bcl-2, p53 or c-erbB-2 were
not associated with CA IX in any of the groups except for the correlation between positive c-
erbB-2 and positive CA IX expression in PNETs. CA IX was also positively associated with
female gender. There was no significant difference in the expression of CA IX between primary
and recurrent tumors in any of the groups. Moreover, there was no correlation between the
tumor type (MBs/PNETs) and CA IX intensity. Interestingly, CA IX-positivity was a marker
of worse outcome in patients with MB/PNET in univariate and multivariate analyses (Figure
4). Generally, CA IX is associated with higher grade, necrosis, and worse CA IX seems to have
several inductors. CA IX is often found in perinecrotic areas. Because necrosis is an uncommon
feature and is not considered to be a significant prognostic factor in MBs, the induction of CA
IX in MBs/PNETs may also involve hypoxia-independent mechanisms. In addition, there is
the evidence that CA IX is expressed in grade I pilocytic astrocytomas, and the immunoposi‐
tivity for CA IX is associated to histopathological features of degeneration and increased
proliferation (our unpublished results).
In children, possible side-effects of therapeutic interventions may be more severe and the exact
biology of hypoxia and its clinical relevance in childhood tumors is still unclear. Thus, further
studies will be needed before novel agents concerning hypoxia can be introduced into pediatric
oncology.
7. Future aspects
The tumor tissue specific CA IX expression has led researchers to propose several novel
treatment strategies. A promising treatment strategy is to use CA selective inhibitors
(Pastoreková et al. 2004). Tumor cells probably use CAs as key enzymes to adapt to the hostile
environment caused by metabolic stress of cancer cells, and thus, acidification facilitates the
spread and invasion of cancer cells (Svastová et al. 2004). High CA IX expression might increase
the capability of cells to infiltrate the neighboring tissue. The inhibition of this process would
potentially disturb the invasion processes of cancer cells.
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Another possible treatment option is to use cancer-specific antibodies. The CA and proteo‐
glycan domains give the molecule a unique extracellular structure. CA IX expression is high
in renal cell carcinoma (Liao et al. 1997) and this has enabled therapeutic trials with high-dose
radiolabeled CA IX antibody (cG250) and CA IX-loaded dendritic cells. Unfortunately, a
significant breakthrough in clinical trials remains to be achieved and in RCC trials are still in
phase II (Stillebroer et al. 2010).
CA IX could also be used as a potential target for immune therapy. Greiner et al. (2006)
found a significant correlation between high mRNA levels of CA IX and a longer overall
survival  in  acute  myeloid  leukemia.  This  might  be  due  to  the  induction  of  a  strong
antileukemic immune response by CA IX. Similar findings have been found in metastatic
RCC patients (Uemura et al. 2006). Vaccination with tumor-RNA pulsed dendritic cells led
to increased numbers of CA IX peptide-specific cytotoxic T76 lymphocytes and IgG levels
without any major adverse event. Metastasis of three patients shrank or even disappeared
and  the  overall  survival  was  longer  for  six  patients.  However,  further  studies  are  re‐
quired to confirm these findings in larger study cohorts.
Bevacizumab, an anti-VEGF antibody, inhibits the developing vasculature of tumors, but
resistance is common. Antiangiogenic therapy induces hypoxia and thus, CA IX. Curious‐
ly, McIntyre et al. (2012) knocked down CAIX expression in a colon cancer and a glioblas‐
toma  cell  lines  and  combined  the  results  with  bevacizumab.  They  found  that  CAIX
expression was associated with increased necrosis and apoptosis in vivo and in vitro. Added
Figure 4. Prognostic significance of CA IX in medulloblastomas/PNETs. Kaplan-Meier curves are shown (P = 0.041, log-
rank test). Nordfors et al. (2010)
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to this, acidity seemed to inhibit CAIX activity, and this may be the mechanism whereby
excess  acid  self-limits  the  build-up  of  extracellular  acid.  It  seems  that  inhibition  of  the
hypoxic  adaptation  to  antiangiogenic  therapy  enhances  bevacizumab  treatment  and
highlights the value of developing small molecules or antibodies which inhibit CAIX for
combination therapy.
8. Conclusions
CA IX has been linked to several cancer tissues, whereas the normal tissue is mostly negative.
This seems to be the case also when different brain tumors are concerned. Malignant astrocy‐
tomas and oligodendrogliomas express CA IX and it has been shown as a useful prognostica‐
tor. Being a hypoxia/necrosis marker, CA IX can be used as a diagnostic tool in the grading of
astrocytomas and oligodendrogliomas. Tumor biopsies containing a small amount of tissue
for diagnosis, are especially good targets. In addition, CA IX is associated to more malignant
phenotype in meningiomas and some other mostly benign brain tumors.
CA IX is present in the most common malignant brain tumor of children, medulloblastoma,
as well as in PNETs. Interestingly, in these tumors CA IX predicts poor prognosis and could
be used as a marker when planning the cancer therapy. Added to this, CA IX has been shown
to be expressed in other pediatric brain tumors, such as ependymomas and pilocytic astrocy‐
tomas, where it is linked to degenerative histopathological features.
CA IX is associated with hypoxia, necrosis, and angiogenesis – features traditionally linked to
the tumorigenesis of brain tumors. Several studies show that CA IX could be used as a target
molecule in adult and pediatric brain tumors. Further clinical trials for cancer treatment are
needed aiming to either eradicate the tumor cell population or turn the tumor into a more
chronic and stable disease.
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